Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
McKesson
Chubb
Johnson and Johnson
Deloitte

Generated: September 24, 2019

DrugPatentWatch Database Preview

Patent: 10,087,175

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,087,175
Title:Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof
Abstract: Methods and compositions for treating cancers such as pancreatic cancer and synovial sarcoma are disclosed. Compounds comprising a sigma-2 receptor-binding moiety and a ferroptosis-inducing moiety are described. At least one described molecular species exhibits an IC.sub.50 value below 5 .mu.M against human pancreatic cancer cells in vitro. Administration of this species promoted shrinkage of pancreatic cancer tumors in a murine model system in vivo, and led to 100% survival of experimental animals over a time course in which control therapies provided only 30% or 40% survival. Methods of synthesis of molecular species are also disclosed.
Inventor(s): Hawkins; William (St. Louis, MO), Mach; Robert (St. Louis, MO), Spitzer; Dirk (St. Louis, MO), Vangveravong; Suwanna (St. Louis, MO), Van Tine; Brian (St. Louis, MO)
Assignee: Washington University (St. Louis, MO)
Application Number:15/301,188
Patent Claims:see list of patent claims

Details for Patent 10,087,175

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Try a Free Trial Washington University (St. Louis, MO) 2034-04-01 RX search
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Try a Free Trial Washington University (St. Louis, MO) 2034-04-01 RX search
Amgen NEUPOGEN filgrastim VIAL 103353 002 1991-02-20   Try a Free Trial Washington University (St. Louis, MO) 2034-04-01 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 003 1991-02-20   Try a Free Trial Washington University (St. Louis, MO) 2034-04-01 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 004 1991-02-20   Try a Free Trial Washington University (St. Louis, MO) 2034-04-01 RX search
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Try a Free Trial Washington University (St. Louis, MO) 2034-04-01 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Cantor Fitzgerald
Julphar
Accenture
Fuji
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.